Eli Lilly’s Retatrutide: 28.3% Weight Loss Over 80 Weeks, Poised to Transform Bariatric Surgery Landscape

May 21, 2026 — Eli Lilly has unveiled another major breakthrough in weight-loss therapeutics. Its triple agonist Retatrutide has achieved positive results in Phase 3 clinical trials, further strengthening the company’s leading position in the weight management sector.

In the 80-week trial, participants receiving the 12mg dose recorded an average weight loss of 28.3%. Nearly half of the participants shed more than 30% of their body weight, while over a quarter lost 35% or more, delivering results comparable to bariatric surgery. Beyond weight reduction, participants also saw notable improvements in multiple cardiovascular risk indicators, including waist circumference, blood lipid levels, blood pressure and inflammatory markers.

Groundbreaking Data: Surgical-level Weight Loss Reshapes Industry Expectations

The TRIUMPH-1 study was a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial. A total of 2,339 overweight and obese adults with a baseline BMI of 27 or above and at least one weight-related comorbidity (without diabetes) were enrolled. The research evaluated the efficacy and safety of Retatrutide administered via once-weekly subcutaneous injection at three dose levels: 4mg, 9mg and 12mg.

All dose groups met the primary weight loss endpoint after 80 weeks of treatment, with efficacy showing a clear dose-dependent trend:

● 12mg group: Average weight loss reached 28.3% (approximately 70.3 pounds / 31.9 kilograms). 45.3% of participants lost 30% or more of their body weight, and 27.2% achieved a weight loss of 35% or higher. The weight loss rate is 2 to 3 times that of conventional weight-loss medications, matching the long-term outcomes of mainstream bariatric procedures such as laparoscopic gastric bypass surgery.

● 9mg group: Average weight loss of 25.9% (approximately 64.4 pounds / 29.2 kilograms).

● 4mg group: Average weight loss of 19.0% (approximately 47.2 pounds / 21.4 kilograms).

● Placebo group: Only an average weight loss of 2.2% (approximately 5.5 pounds / 2.5 kilograms), a stark contrast to the treatment groups.

Extended follow-up data further validated its performance. Among participants with a baseline BMI of 35 or higher (severe obesity), those on the 12mg dose saw their average weight loss rise to 30.3% after 104 weeks of treatment, proving its sustained long-term efficacy. Dan Skovronsky, Chief Scientific Officer and President of Product Development at Eli Lilly, commented: "Weight loss exceeding 30% is an unprecedented achievement in the industry. Retatrutide is taking obesity treatment to an entirely new level."

More Than Weight Loss: Improved Cardiovascular Health and Comprehensive Metabolic Benefits

As a triple receptor agonist targeting GLP-1, GIP and GCGR pathways, Retatrutide offers far more than effective weight management. It markedly improves multiple key cardiovascular risk factors, delivering dual benefits for weight control and cardiac health.

Key improvements observed in the 12mg group over 80 weeks are as follows:

● Significant reduction in waist circumference and targeted loss of visceral fat;

● Lower levels of low-density lipoprotein ("bad cholesterol") and triglycerides, leading to an optimized lipid profile;

● Systolic blood pressure decreased by 4 to 8 mmHg and diastolic blood pressure by 2 to 4 mmHg. Every 5 mmHg drop in systolic blood pressure can reduce the risk of cardiovascular events by 10%;

● Substantial decline in high-sensitivity C-reactive protein, alleviating systemic inflammation.

Retatrutide also demonstrates potential liver-protective effects. Phase 2 data shows it can reduce liver fat content by an average of 82%, an effect comparable to bariatric surgery, bringing new hope for patients with fatty liver disease.

Restructuring the Industry Landscape: Eli Lilly Extends Lead, Bariatric Surgery Faces New Challenges

From tirzepatide, a dual agonist, to Retatrutide, a triple agonist, Eli Lilly has consistently driven innovation across the GLP-1 landscape. The success of Retatrutide’s Phase 3 trials has widened its lead over competitors and solidified its dominant position in the global weight-loss market.

Currently, bariatric surgeries including gastric bypass and sleeve gastrectomy remain the primary treatment for patients seeking over 30% weight loss. However, such procedures carry inherent drawbacks: surgical trauma, potential postoperative complications, long recovery periods, high costs and limited eligibility. In contrast, Retatrutide is administered via once-weekly subcutaneous injection. Its non-invasive nature, convenience and comparable efficacy pose a strong challenge to the traditional bariatric surgery market.

Industry analysts predict Retatrutide is likely to gain regulatory approval in 2027. Upon launch, it is expected to capture a large share of the severe obesity treatment market, gradually replacing a portion of bariatric surgery procedures and evolving into the new gold standard for obesity and metabolic disorder management. Its favorable cardiovascular benefits also lay a solid foundation for future approval in indications involving obesity combined with cardiovascular diseases.

Favorable Safety Profile: Mild Adverse Reactions and Good Overall Tolerability

Retatrutide was well tolerated throughout the Phase 3 trial. Most adverse events were mild to moderate, occurring mainly in the early stage of treatment and easing over time. The most common side effects were gastrointestinal issues such as nausea, vomiting, diarrhea and constipation, consistent with the known safety profile of GLP-1 class drugs. The treatment discontinuation rate due to adverse reactions stood at approximately 18.2% for the 12mg group and 12.2% for the 9mg group, with an even lower rate in the 4mg group. No severe hepatorenal toxicity or fatal adverse events were reported.

The Success of Retatrutide: Ushering in a New Era for Pharmacological Obesity Treatment

The groundbreaking success of Retatrutide marks the official arrival of the triple agonist era in global obesity treatment. As a professional pharmaceutical enterprise deeply engaged in the metabolic disease sector, Dengyue Pharmaceuticals keeps a close eye on cutting-edge developments in the GLP-1 field and continuously tracks the clinical progress and application value of Retatrutide. The launch of this drug aligns perfectly with Dengyue Pharmaceuticals’ strategic layout in weight management and metabolic disorder therapies. For the first time, pharmaceutical treatment has achieved results on par with or even superior to bariatric surgery, offering millions of patients with obesity and metabolic diseases a non-invasive, highly effective new treatment option.